In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Pancragen (KEDW) | Natural peptide Exenatide (exendin-4) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Natural peptide | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 35 | 3,292 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 449 (415 in people) | |
| Status | |||
| Approval | Not recorded | ||
| Sport (WADA) | |||
| Registered trials | None registered | 322 · 11 active54 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Pancragen (KEDW) | Exenatide (exendin-4) |
|---|---|---|
| Glycemic controlMetabolic and weight | 15510 | 8967171727 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Byetta says: “Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus” No central EU authorisation (EMA).
| Receptor activity and mechanismEndocrine and hormones | 19217 | 2862818573 |
|---|
| Cardiometabolic risk factorsCardiovascular | 11 | 66 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Pancragen (KEDW) found in ClinicalTrials.gov.
Top 3 of 322 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
AstraZeneca14,752 participants18 Jun 2010 to 24 Apr 2017
Type 2 Diabetes Mellitus
AstraZeneca1,036 participantsSept 2009 to Aug 2012
Type 2 Diabetes Mellitus
AstraZeneca1,029 participantsSept 2006 to Mar 2011
Type 2 Diabetes Mellitus
54 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Pancragen (KEDW) | Exenatide (exendin-4) |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in % | No randomized trial result 15 results from other study designs. | 41% Treatment failure n = 9772012 |
| Receptor activity and mechanismNervous system and cognitionCompared as: value in the arm that got the peptide, in % | No randomized trial result 19 results from other study designs. | −18.75% Endothelin-1 decrease · Shown as a change. The study reports a endothelin-1 decrease of this size. 26 weeksn not reported2014 |
No randomized trial result
15 results from other study designs.
41%
Treatment failure
n = 9772012
No randomized trial result
19 results from other study designs.
−18.75%
Endothelin-1 decrease · Shown as a change. The study reports a endothelin-1 decrease of this size.
26 weeksn not reported2014